Raymond James & Associates Biomarin Pharmaceutical Inc Transaction History

Raymond James & Associates

  • $150 Billion
  • Q2 2024

A detailed history of Raymond James & Associates transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Raymond James & Associates holds 62,884 shares of BMRN stock, worth $4.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
62,884
Previous 70,193 10.41%
Holding current value
$4.29 Million
Previous $6.13 Million 15.55%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024
SELL
$74.43 - $92.22 $544,008 - $674,035
-7,309 Reduced 10.41%
62,884 $5.18 Million
Q1 2024

Apr 22, 2024
BUY
$83.81 - $99.0 $1.26 Million - $1.48 Million
14,982 Added 27.14%
70,193 $6.13 Million
Q4 2023

Jan 16, 2024
BUY
$76.22 - $98.51 $15,320 - $19,800
201 Added 0.37%
55,211 $5.32 Million
Q3 2023

Oct 24, 2023
SELL
$85.07 - $94.48 $30,369 - $33,729
-357 Reduced 0.64%
55,010 $4.87 Million
Q2 2023

Jul 25, 2023
BUY
$86.68 - $100.3 $444,321 - $514,137
5,126 Added 10.2%
55,367 $4.8 Million
Q1 2023

Apr 14, 2023
SELL
$87.74 - $117.27 $892,140 - $1.19 Million
-10,168 Reduced 16.83%
50,241 $4.89 Million
Q4 2022

Feb 08, 2023
BUY
$80.93 - $108.63 $203,700 - $273,421
2,517 Added 4.35%
60,409 $6.25 Million
Q3 2022

Oct 25, 2022
SELL
$82.16 - $96.94 $677,162 - $798,979
-8,242 Reduced 12.46%
57,892 $4.91 Million
Q2 2022

Aug 12, 2022
BUY
$71.48 - $86.85 $1.39 Million - $1.68 Million
19,378 Added 41.44%
66,134 $5.48 Million
Q1 2022

May 11, 2022
SELL
$74.28 - $92.69 $7.77 Million - $9.69 Million
-104,537 Reduced 69.1%
46,756 $3.61 Million
Q4 2021

Feb 08, 2022
SELL
$71.72 - $91.47 $36,935 - $47,107
-515 Reduced 0.34%
151,293 $13.4 Million
Q3 2021

Nov 02, 2021
BUY
$74.77 - $85.47 $1.26 Million - $1.44 Million
16,857 Added 12.49%
151,808 $11.7 Million
Q2 2021

Aug 11, 2021
BUY
$75.51 - $84.79 $457,515 - $513,742
6,059 Added 4.7%
134,951 $11.3 Million
Q1 2021

May 14, 2021
SELL
$74.73 - $90.69 $5.55 Million - $6.73 Million
-74,211 Reduced 36.54%
128,892 $9.73 Million
Q4 2020

Feb 12, 2021
BUY
$72.61 - $90.2 $2.37 Million - $2.94 Million
32,613 Added 19.13%
203,103 $17.8 Million
Q3 2020

Nov 04, 2020
SELL
$71.87 - $131.03 $1.87 Million - $3.41 Million
-26,046 Reduced 13.25%
170,490 $13 Million
Q2 2020

Jul 28, 2020
SELL
$79.55 - $124.22 $216,057 - $337,381
-2,716 Reduced 1.36%
196,536 $24.2 Million
Q1 2020

Apr 21, 2020
BUY
$71.37 - $96.85 $2.51 Million - $3.41 Million
35,194 Added 21.45%
199,252 $16.8 Million
Q4 2019

Feb 12, 2020
SELL
$64.27 - $86.37 $1.36 Million - $1.83 Million
-21,179 Reduced 11.43%
164,058 $13.9 Million
Q3 2019

Nov 07, 2019
SELL
$67.4 - $85.11 $643,939 - $813,140
-9,554 Reduced 4.9%
185,237 $12.5 Million
Q2 2019

Aug 06, 2019
BUY
$80.35 - $93.9 $759,709 - $887,824
9,455 Added 5.1%
194,791 $16.7 Million
Q1 2019

May 06, 2019
BUY
$84.2 - $98.62 $923,505 - $1.08 Million
10,968 Added 6.29%
185,336 $16.5 Million
Q4 2018

Feb 11, 2019
BUY
$80.14 - $106.07 $9,616 - $12,728
120 Added 0.07%
174,368 $14.8 Million
Q3 2018

Nov 14, 2018
BUY
$93.92 - $105.72 $589,723 - $663,815
6,279 Added 3.74%
174,248 $16.9 Million
Q2 2018

Aug 14, 2018
BUY
$76.01 - $99.03 $4.67 Million - $6.08 Million
61,434 Added 57.67%
167,969 $15.8 Million
Q1 2018

May 14, 2018
BUY
$77.67 - $92.63 $432,000 - $515,208
5,562 Added 5.51%
106,535 $8.64 Million
Q4 2017

Feb 14, 2018
BUY
$80.76 - $95.13 $1.49 Million - $1.76 Million
18,473 Added 22.39%
100,973 $9 Million
Q3 2017

Nov 13, 2017
SELL
$80.6 - $94.95 $544,856 - $641,862
-6,760 Reduced 7.57%
82,500 $7.68 Million
Q2 2017

Aug 14, 2017
BUY
N/A
89,260
89,260 $8.11 Million

Others Institutions Holding BMRN

# of Institutions
631
Shares Held
185M
Call Options Held
1.63M
Put Options Held
1.2M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.7B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email